AstraZeneca's TROPION-BREAST01 Trial: Mixed Results Reported
AstraZeneca PLC reported mixed results from its TROPION-BREAST01 trial. The progression-free survival endpoint was met, but overall survival results for datopotamab deruxtecan were not statistically significant compared to chemotherapy. The safety profile remained consistent with no new concerns.
AstraZeneca PLC announced mixed outcomes from its TROPION-BREAST01 clinical trial. The study achieved its dual primary endpoint for progression-free survival.
However, final overall survival results for datopotamab deruxtecan were not statistically significant when compared with chemotherapy.
The company's safety profile analysis revealed consistency with previous assessments, showing no new safety concerns.
(With inputs from agencies.)
Advertisement
ALSO READ
Kate, Princess of Wales, has completed chemotherapy and will return to a light programme of public engagements, reports AP.
Princess Kate Completes Chemotherapy, Eyes Recovery
Princess Kate's Journey: Completing Chemotherapy and Embracing Hope
Princess of Wales Set to Resume Public Duties After Chemotherapy
Princess Kate Completes Chemotherapy, Embarks on Public Engagements